相关实验视频

Updated: May 17, 2025

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

国际美丁通过抑制通过AMPK/GTPCH-I/BH4通路的eNOS解来保护周周毛细血管,并缓解AKI后的CKD

Hui Lin¹, Juan Pan¹, Junhua Zhang¹

¹Department of Nephrology, Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China; Shanxi Kidney Disease Institute, Taiyuan, People's Republic of China; Kidney Research Center of Shanxi Medical University, Taiyuan, People's Republic of China.

Free radical biology & medicine

|April 14, 2025

概括

国际美丁 (IMD) 通过保护周周毛细血管 (PTC) 来保护急性损伤 (AKI) 后的纤维化进展. IMD激活AMPK/GTPCH-I/BH4/eNOS通路,减少氧化应激和内皮损伤,从而抑制过渡到慢性病 (CKD).

科学领域:

腎臟病學 (nephrology) 是一種醫學.
心血管生物学心血管生物学
细胞和分子医学细胞和分子医学

背景情况:

从急性损伤 (AKI) 到慢性病 (CKD) 的进展涉及周周毛细管 (PTC) 稀缺和纤维化.
在AKI-CKD中,内皮细胞损伤和PTC损失与来自未结合内皮氧化合成酶 (eNOS) 的反应性氧物种 (ROS) 有关.
已知Intermedin (IMD) 通过AMPK激活抑制eNOS解,但其在AKI-CKD过渡中的作用尚未完全理解.

研究的目的:

调查Intermedin (IMD) 在从AKI过渡到CKD中的作用.
阐明IMD在周周毛细血管 (PTC) 和内皮细胞上的保护机制.
确定AMPK/GTPCH-I/BH4/eNOS通路在IMD对氧化应激的保护作用中的参与.

主要方法:

使用IMD缺陷 (IMD^-/-) 的小鼠和野生型 (IMD^+/+) 的 littermates 在脏缺血/再损伤 (IRI) 模型中评估AKI-CKD过渡,PTC密度,内皮损伤和脏ROS.
使用人类静脉内皮细胞 (HUVEC) 的低氧/低氧化 (HR) 模型来研究IMD对内皮细胞和ROS产生的影响.
使用特定的抑制剂和激活剂研究IMD对AMPK/GTPCH-I/BH4/eNOS通路的影响.

主要成果:

与野生类型小鼠相比,IMD 缺乏症加剧了 AKI 后的损伤,纤维化,PTC 稀缺和氧化应激.
在体外,IMD治疗显著抑制了低氧/再氧化诱导的eNOS解和HUVEC中的ROS产生,与N-乙半氨酸相比.
IMD的保护作用通过激活AMPK/GTPCH-I/BH4通路来介导,从而抑制了eNOS解和随后的氧化应激.

结论:

间隔素 (IMD) 在防止从AKI发展为CKD方面发挥着至关重要的作用.
IMD通过激活AMPK/GTPCH-I/BH4/eNOS通路来保护PTC的内皮细胞,从而减少氧化应激.
向IMD介导的途径为抑制AKI-CKD过渡和相关纤维化提供了潜在的治疗策略.

关键词:

这就是AMPKK.急性损伤是什么?急性损伤是什么?慢性脏疾病慢性脏疾病在GTPCH-I中.在此期间,Intermedin.在 eNOS eNOS 中使用.

更多相关视频

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

The Mouse Isolated Perfused Kidney Technique

The Mouse Isolated Perfused Kidney Technique

Published on: November 17, 2016

相关概念视频

Drug Elimination by Renal Route: Tubular Secretion

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...